MX9202736A - [(arilalquilpiperidin-4-il)metil)]-2a,3,4,5,-tetrahidro-1(2h)-acenafti len-1-onas y compuestos afines, un procedimiento para su preparacion y su empleo como medicamentos. - Google Patents

[(arilalquilpiperidin-4-il)metil)]-2a,3,4,5,-tetrahidro-1(2h)-acenafti len-1-onas y compuestos afines, un procedimiento para su preparacion y su empleo como medicamentos.

Info

Publication number
MX9202736A
MX9202736A MX9202736A MX9202736A MX9202736A MX 9202736 A MX9202736 A MX 9202736A MX 9202736 A MX9202736 A MX 9202736A MX 9202736 A MX9202736 A MX 9202736A MX 9202736 A MX9202736 A MX 9202736A
Authority
MX
Mexico
Prior art keywords
arilalquilpiperidin
acenafti
tetrahidro
onas
len
Prior art date
Application number
MX9202736A
Other languages
English (en)
Inventor
Raymond W Kosley Jr
Bettina Spahl
Original Assignee
Hoechst Roussel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma
Publication of MX9202736A publication Critical patent/MX9202736A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Lubricants (AREA)
  • Pyridine Compounds (AREA)
MX9202736A 1991-06-07 1992-06-08 [(arilalquilpiperidin-4-il)metil)]-2a,3,4,5,-tetrahidro-1(2h)-acenafti len-1-onas y compuestos afines, un procedimiento para su preparacion y su empleo como medicamentos. MX9202736A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/713,249 US5106856A (en) 1991-06-07 1991-06-07 [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds

Publications (1)

Publication Number Publication Date
MX9202736A true MX9202736A (es) 1993-01-01

Family

ID=24865395

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9202736A MX9202736A (es) 1991-06-07 1992-06-08 [(arilalquilpiperidin-4-il)metil)]-2a,3,4,5,-tetrahidro-1(2h)-acenafti len-1-onas y compuestos afines, un procedimiento para su preparacion y su empleo como medicamentos.

Country Status (23)

Country Link
US (1) US5106856A (es)
EP (1) EP0517221B1 (es)
JP (1) JP2961013B2 (es)
KR (1) KR100234445B1 (es)
AT (1) ATE131814T1 (es)
AU (1) AU646784B2 (es)
CA (1) CA2070714A1 (es)
CZ (1) CZ284591B6 (es)
DE (1) DE69206889T2 (es)
DK (1) DK0517221T3 (es)
ES (1) ES2081517T3 (es)
FI (1) FI101297B (es)
GR (1) GR3018558T3 (es)
HU (1) HU217967B (es)
IE (1) IE72199B1 (es)
IL (1) IL102118A (es)
MX (1) MX9202736A (es)
NO (1) NO178889C (es)
NZ (1) NZ243013A (es)
PL (1) PL169423B1 (es)
RU (1) RU2043989C1 (es)
TW (1) TW206214B (es)
ZA (1) ZA924109B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW248556B (es) * 1993-01-18 1995-06-01 Takeda Pharm Industry Co
US6939879B2 (en) * 1998-08-28 2005-09-06 Aventis Pharmaceuticals Inc. Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia
EP1891954A3 (en) 1998-09-30 2009-01-14 Takeda Pharmaceutical Company Limited Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
CN102905532A (zh) 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
NO3034079T3 (es) 2010-11-15 2018-06-09
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
MX2016007808A (es) 2013-12-20 2016-09-07 Agenebio Inc Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro congnitivo.
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
CN113264939A (zh) 2015-06-19 2021-08-17 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2019246300A1 (en) 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2589934A (en) * 1950-08-24 1952-03-18 Abbott Lab 2-aminomethyl-tetrahydroacenapthones-1 and their preparation
US3391178A (en) * 1964-12-30 1968-07-02 Ernest E. Campaigne Dialkylaminoalkyl 1-oxo-2alpha, 3, 4, 5-tetrahydroacenaphthen-2alpha-carboxylates
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2969359B2 (ja) * 1989-01-13 1999-11-02 武田薬品工業株式会社 環状アミン化合物

Also Published As

Publication number Publication date
AU1801592A (en) 1992-12-10
FI922592A0 (fi) 1992-06-04
AU646784B2 (en) 1994-03-03
HUT65605A (en) 1994-07-28
NZ243013A (en) 1995-04-27
FI101297B1 (fi) 1998-05-29
DK0517221T3 (da) 1996-04-22
HU9201887D0 (en) 1992-08-28
NO922223D0 (no) 1992-06-05
HU217967B (hu) 2000-05-28
ES2081517T3 (es) 1996-03-16
EP0517221B1 (en) 1995-12-20
GR3018558T3 (en) 1996-03-31
CZ284591B6 (cs) 1999-01-13
ATE131814T1 (de) 1996-01-15
DE69206889D1 (de) 1996-02-01
IE921840A1 (en) 1992-12-16
JP2961013B2 (ja) 1999-10-12
DE69206889T2 (de) 1996-05-30
IL102118A (en) 1996-05-14
FI922592A (fi) 1992-12-08
RU2043989C1 (ru) 1995-09-20
KR930000483A (ko) 1993-01-15
IE72199B1 (en) 1997-04-09
EP0517221A1 (en) 1992-12-09
FI101297B (fi) 1998-05-29
ZA924109B (en) 1993-02-24
PL169423B1 (pl) 1996-07-31
CS171392A3 (en) 1992-12-16
NO178889C (no) 1996-06-26
TW206214B (es) 1993-05-21
NO178889B (no) 1996-03-18
NO922223L (no) 1992-12-08
PL294803A1 (en) 1993-07-26
IL102118A0 (en) 1993-01-14
KR100234445B1 (ko) 1999-12-15
JPH06116237A (ja) 1994-04-26
US5106856A (en) 1992-04-21
CA2070714A1 (en) 1992-12-08

Similar Documents

Publication Publication Date Title
MX9202736A (es) [(arilalquilpiperidin-4-il)metil)]-2a,3,4,5,-tetrahidro-1(2h)-acenafti len-1-onas y compuestos afines, un procedimiento para su preparacion y su empleo como medicamentos.
ES2094840T3 (es) 1-(pirido(3,4-b)-1,4-oxazinil-4-il)-1h-indoles, compuestos intermedios y un procedimiento para su preparacion, y su uso como medicamentos.
ES2109953T3 (es) 1,2,3,4-tetrahidrociclopent(b)indoles, 1,2,3,3a,4,8a-hexahidrociclopent(b)indoles sustituidos y compuestos relacionados, compuestos intermedios y un procedimiento para su preparacion y su uso como medicamentos.
DK613687A (da) Kondenserede heterocycliske tetrahydroaminoquinolinoler og beslaegtede forbindelser, fremgangsmaade til deres fremstilling og deres anvendelse som laegemidler
FI895288A0 (fi) 1,2,3,4-tetrahydro-1,9-akridinaminer, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
ES2064533T3 (es) Acido(1,2,3,4-tetrahidro-9-acridinimino)-ciclohexanocarboxilico y compuestos relacionados, un procedimiento para su preparacion y su uso como medicamentos.
ES2096800T3 (es) Benzo(b)tiofen-3-il-piperazinas, un procedimiento para su preparacion y su uso como medicamentos.
IL111404A (en) Pharmaceutical compositions for the enhancement ofmemory and cognition comprising 3-aryl-4-alkyl and 4,5-dialkyl-4H-1,2,4-triazoles and some such novel compounds
MX25922A (es) Pirido (3,4-b) pirrolo (1,2-e)(1,4,5)oxadiazepinasy compuestos analogos relacionados un procedimiento para su preparacion y su uso como medicamentos
ES2072334T3 (es) Derivados de 4,5,5a,6-tetrahidro-3h-isoxazolo(5,4,3-kl)acridinas, un procedimiento para su preparacion y su uso como medicamentos.
DK0587048T3 (da) Heteroarenylpiperaziner, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees